(NASDAQ: URGN) Urogen Pharma's forecast annual revenue growth rate of 48.09% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.64%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.1%.
Urogen Pharma's revenue in 2024 is $82,713,000.On average, 2 Wall Street analysts forecast URGN's revenue for 2024 to be $3,390,882,396, with the lowest URGN revenue forecast at $3,378,086,613, and the highest URGN revenue forecast at $3,403,678,178. On average, 2 Wall Street analysts forecast URGN's revenue for 2025 to be $5,874,458,498, with the lowest URGN revenue forecast at $5,578,961,225, and the highest URGN revenue forecast at $6,169,955,771.
In 2026, URGN is forecast to generate $9,489,352,395 in revenue, with the lowest revenue forecast at $9,489,352,395 and the highest revenue forecast at $9,489,352,395.